David Bumcrot

Chief Scientific Officer at CAMP4 Therapeutics

David Bumcrot, Ph.D., is Chief Scientific Officer and Senior Vice President of Research, where he oversees the Biology, Data Science, and Discovery teams.

Prior to joining CAMP4, Dr. Bumcrot led groups at innovative biotech companies advancing novel technologies towards clinical development. He was one of the first employees at Alnylam pharmaceuticals where he spent ten years working to make RNA interference-based drugs a reality for multiple indications, including key contributions to a first-in-class systemically administered siRNA therapeutics tested in an oncology clinical trial. Dr. Bumcrot then moved on to Editas Medicine where his team established the company’s initial therapeutic programs utilizing groundbreaking CRISPR technology.

Dr. Bumcrot received his Bachelor of Science degree from Cornell University and a Ph.D. in molecular biology from the University of Pennsylvania. He completed a post-doctoral fellowship at Harvard University.

Location

Cambridge, United States

Links

Previous companies


Org chart


Teams


Offices


CAMP4 Therapeutics

1 followers

CAMP4 Therapeutics is pioneering a new approach to upregulate genes by targeting regulatory RNA using programmable oligonucleotide therapeutics.